Table 3 Lipid-lowering drug treatment
| Treatment | Full analysis set (n = 2703) |
|---|---|
| Current treatment | |
| Statin monotherapy | 2645 (97.9) |
| Fibrates | 7 (0.3) |
| Ezetimibe | 2 (0.1) |
| Statin + fibrates | 22 (0.8) |
| Statin + ezetimibe | 23 (0.9) |
| Statin + fibrates + ezetimibe | 2 (0.1) |
| Missing | 2 (0.1) |
| Reason for treatment | |
| Primary prevention | 943 (34.9) |
| Secondary prevention | 1760 (65.1) |